Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression

This study has been completed.
Stanley Medical Research Institute
Information provided by:
Zentrum für Integrative Psychiatrie Identifier:
First received: March 7, 2006
Last updated: May 19, 2006
Last verified: March 2006
We investigate whether the add-on specific antitoxoplasmatic medication has positive effects in individuals with schizophrenia or major depression seropositive for Toxoplasma gondii (TG) infection. As TG modulates neurotransmitter metabolism affecting serotonin and dopamine we hypothesize that this chronic persistent infection might play a role for depressive and psychotic symptomatology. Therefore, on the basis of an ex juvantibus approach, specific anti TG medication might further improve psychiatric symptomatology in affected patients. This is investigated in a double-blind, placebo-controlled, randomized treatment trial.

Condition Intervention Phase
Major Depression
Drug: daraprim
Drug: pyrimethamine
Drug: folinic acid
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Effect of Add-on Anti-Toxoplasmosis Treatment on Parameters Defining Toxoplasma Gondii Infection and on Psychopathology in Patients With Schizophrenia or Major Depression Serologically Positive for Toxoplasma Gondii - Phase 3 Study

Resource links provided by NLM:

Further study details as provided by Zentrum für Integrative Psychiatrie:

Primary Outcome Measures:
  • Psychopathology ratings

Secondary Outcome Measures:
  • TG infection parameters

Estimated Enrollment: 40
Study Start Date: January 2002
Estimated Study Completion Date: September 2005

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Schizophrenia or Major Depression
  • Both genders
  • Adult
  • Patients are able to give informed consent

Exclusion Criteria:

  • Additional diagnosis of substance abuse/dependency
  • Continuous treatment with medication not compatible with study medication
  • Medical status not compatible with study medication
  • Any condition that increases study risk considerably
  • Pregnancy, nursing
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00300404

Sponsors and Collaborators
Zentrum für Integrative Psychiatrie
Stanley Medical Research Institute
Principal Investigator: Dunja Hinze-Selch, MD Zentrum für Integrative Psychiatrie
  More Information Identifier: NCT00300404     History of Changes
Other Study ID Numbers: TOXO-KI-TT  SMRI grant # 01T-404 
Study First Received: March 7, 2006
Last Updated: May 19, 2006
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Zentrum für Integrative Psychiatrie:
Affective Disorder

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Behavioral Symptoms
Mood Disorders
Mental Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Folic Acid
Protective Agents
Physiological Effects of Drugs
Vitamin B Complex
Growth Substances
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Folic Acid Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on October 21, 2016